Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ON012380

Known as: ON 012380, ON-012380 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Benzene Derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells 
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Proliferation centers in chronic lymphocytic leukemia: the niche where NF-κB activation takes place
Proliferation centers in chronic lymphocytic leukemia: the niche where NF-κB activation takes place 
  • figure 3
  • table 1
Is this relevant?
2009
2009
ON012380: A Non-ATP Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs
Abstract : Because it is now apparent that a significant proportion of patients chronically treated with imatinib develop… Expand
  • table 1
  • figure 1
Is this relevant?
Review
2006
Review
2006
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid… Expand
Is this relevant?
Review
2006
Review
2006
The Second Generation of BCR-ABL Tyrosine Kinase Inhibitors
Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia… Expand
Is this relevant?
Review
2006
Review
2006
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that specifically inhibits the BCR-ABL… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia… Expand
  • figure 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE